December 30, 2020

Cryptocurrencies and precious metal are bonds with zero real interest rate

This is not a write-up on individual stocks, but with all the buzz going on, I'd like to share my personal view on cryptocurrencies and precious metal for those who are interested. Disclaimer: I own both in my portfolio.

Many like to criticize crypto and precious metals because they are not income producing assets. Here is my question: why do people buy bonds? Because bond holders earn interest income by lending money to others. However, many don't know that the earned interest is denoted in fiat currencies, not the real purchasing power. The increased account balance in your bank may well be delusional to make you feel you have more money to buy more goods and services.

For example, you love eating apples and one apple costs you $1 today. You have $100 cash which can be converted into 100 apples. Now you decide to invest instead and use all your cash to purchase a bond of $100 with an interest rate of 10%. The next year you are paid the interest $10, and you thought you have $110 cash to buy apples. However, what if I tell you one apple has become more expensive and will cost you $2 now? Congratulations, you earned interest, but your money can buy you only 55 apples. This is so-called inflation.

The example above is extreme because we don’t have 100% inflation rate in any developed nations, but if you understand the logic, you will see this is exactly what is happening in most developed nations due to all the loose monetary policy and money printing, including the US, EU and Japan - the real interest rate is negative. Real interest rate = nominal interest rate - inflation rate. When the inflation is higher than the nominal interest rate, holding bond with negative real interest rate over time will actually decrease your purchasing power. I'm not making this up. This is today's real interest rate published by U.S. Department of the Treasury - the real interest rate is sitting negative for US government bonds with all maturities. Inflation is the fiat currency depreciating against all other goods and services.

In the old barter economy where people directly exchange goods and services for other goods and services, how much you can exchange for apples with other goods depends on the demand and supply of both products. For example, you have 1 gram of gold that is worth $100. Assume both apples and gold have constant demand and supply over time. 1 gram of gold can exchange for 100 apples ($1 per apple) today; next year when the price of apple increases to $2, the 1 gram of gold you have will also increase to $200 (think the fiat currency is just a unit of account), and can still exchange for 100 apples. Regardless of the fiat currency movement, the purchasing power remains the same.

You can consider precious metal and cryptocurrency as a special bond with zero real interest rate that retains your purchasing power. They can perfectly hedge the inflation risk, but that has one condition - the demand and supply for them is relatively stable compared to other goods and services. If a new technology is invented to increase the production of apples at lower cost, given all the other conditions the same, 1 gram of gold can actually buy you more than 100 apples now because the supply of apples has increased.

Let’s examine the supply and demand of precious metal and cryptocurrencies. Supply is easy. Gold discovery and mining is relatively stable (gold production may have peaked steady). Unless people invent a technology to extract gold from sea water in a cheap way, I don't expect much surge in gold supply. Cryptocurrencies are more straightforward. One of the things that supporters like to tout about crypto is the capped supply of Bitcoin. Bitcoin's supply is strictly limited to 21 million coins. After halving of Bitcoin this year, the new supply will become half of the prior amount.

Switching to the demand side which is trickier. The demand for something is not necessarily based on the usability of a certain product. Besides decoration and jewelries, gold doesn't have much industry application, but people like its rarity and stability so the value of gold has been persisting over thousands of years throughout our human history. It is the consensus among the crowd that creates demand and assigns a price to a product. The value of gold will not change much if just a few people think gold is absolutely useless and decide never to own any gold. It really doesn't matter what YOU think about gold. When the majority of the population start to like, want and desire gold, the demand will be developed. Once the demand hits a critical mass, even the early doubters will be forced into adopters because they have no other choice but to own some gold when overwhelmingly majority has accepted it. It's just crowd psychology.

Similarly, many crypto bears often argue that cryptos are useless, inconvenient, waste of energy, etc. Keep in mind that the demand of a product is not determined by its usability. It is people's perception that creates the demand and value. Just like precious metals, cryptocurrencies are also stable and have limited supplies. Think about it - over the past few years, do more or less people hear about cryptocurrencies? Do more or less people accept it as an asset or payment? Just look at the adoption of crypto by institutions and the growing inflows into GBTC; the answers are clear to me. Thanks to the bears, they also played a very important role to increase the awareness among the crowd. Ask people around and see how many actually own cryptocurrencies - I believe we are still in a very early stage of adoption but it's important to know where the trend is going. However, not all the cryptocurrencies are created the same - I would stick with the ones on the top of the list which are most recognized and accepted. Again, it is how other people think that matters the most to determine the demand. Just follow the trend.

Not many people realize the safe government bonds they hold are producing negative real interest rate for them. These investors may see an increase in their bank balance with the earned interest, but by the time when they need to convert their bonds into real goods and services, they will realize their purchasing power has become less by holding the bond. Now, if I present you with i) a bond with a negative real interest rate and ii) an asset that has zero real interest rate, what would you pick?

This is why I believe the potential demand for precious metal and cryptocurrencies is far from fully realized. When the majority starts to understand the logic above, animal spirit will drive the crowd into precious metal and cryptocurrencies, increasing the demand and price of the asset. The increased price will attract even more buyers to follow, pushing up the demand even higher. At that time, precious metals and/or cryptocurrencies may well become another bubble. That's when I will sell, but right now it's far from there. 

The Bitcoin price chart is a bonus for those curious technical chartists. I'm not saying right now it's a low risk point to buy BTC, but look at the big volume bars when the price was at the bottom since 2019. It is obvious to me that some big players are accumulating. In contrast, the volume during the distribution phase was really nothing comparable when the price hit the top in 2017. The on-going upward trend has been confirmed by an increasing volume along with it. If the 2017 "bubble" is mostly created by retail investors, the run-up this time will be driven by institutions. It will go much higher from here. I will hold until the smart money distributes. 

Footnote: in my opinion, cryptocurrency is never going to be a replacement to our current currency system exactly due to its limited supply. When the economy grows and GDP increases over time, ideally, we need the equivalent increase in money supply (maybe slightly more) to denote the additional productivity. Money is important to facilitate transactions in an economy. When there is not enough money in circulation, deflation will happen where goods and services become cheaper compared to the currency. When deflation happens, people would rather hold cash and not spend it because they expect the goods and services to become cheaper in the future. When people are reluctant to spend and make transactions, the economy will shrink and collapse.

Before industrial revolution, our global economies are pretty stagnant without much growth up until 20th century. Gold/silver standard had worked well because the supply of gold and silver are relatively stable too. However, the supply of gold or silver becomes insufficient to support the exponential growth of economies after 20th century, and that's why we see all countries have abandoned gold or silver standard. This is the same reason why Bitcoin can never replace our current currency system.


December 29, 2020

Buy BXRX when there is blood in the streets

Happy holidays and Happy New Year! Full disclosure: I'm already fully invested in Baudax Bio Inc (BXRX) with an average cost basis around $1/share. Before this year ends, I want to take some time to write down this thesis for my own reference, and hopefully this can provide some insights to someone who is also interested in this beaten-down biotech company.

What I like about BXRX:
  • Low risk entry: a very strong accumulation base on chart with a sexy gap to fill
  • Two private placements in total $20M have offering prices of $1.165 and $1.185 per share, at a premium to the market (this is very important)
  • Commercial launch of FDA-approved drug Anjeso, a non-opioid long-acting IV treatment, with significant commercial opportunities
  • Founder CEO Gerri Henwood has over 2.5M shares to vest (I like when management has their skin in the game)
  • A spin-off from Recro Pharma Inc (REPH) on 11/22/2019. (I like it more when a stock is under selling pressure that has nothing to do with its fundamentals)
  • They should be good without raising more capital for another 12 months
  • Non-opioid drug theme
What I don't like about BXRX:
  • Mismanaged capital raise earlier this year. The # of shares increased quickly from 17M shares in March to 42M now (78M fully diluted)
  • Revenue ramps up slower than expected due to hospital shutdown caused by COVID

Overview
BXRX owns Anjeso, a non-opioid, long-acting IV drug for moderate to severe acute pain. Anjeso was originally acquired by Recro Pharma Inc (REPH) as an asset deal from Alkermes (ALKS), along with a contract development and manufacturing organization (CDMO) business, together for $50M in 2015. At that time, Anjeso was just ready for starting Phase 3. After a few years of trial and a couple of back and forth with FDA, Anjeso finally received FDA approval in Feb 2020. 

Near the end of 2019, with the anticipation of the receipt of FDA approval, REPH decided to spin off BXRX from its CDMO business and prepare for the commercial launch of the new drug. BXRX is targeting at rapidly growing non-opioid market which addresses the need to reduce the reliance on opioid for acute pain management. According to BCC Research, "the global market for non-opioid pain treatments should grow from $13.8 billion in 2019 to $31.8 billion by 2024 at a compound annual growth rate (CAGR) of 18.3% for the period of 2019-2024."


Low risk accumulation phase
Chart is always my first key to understand a company. Look at the beautiful flat line since November 2020, together with the huge volume spikes over the same period. The stock is absolutely unloved by most and gets dumped harshly by the market. Apparently, this has shown a great support at this price level - someone is accumulating all the shares sold by panicking crowd. That's why the stock didn't keep plummeting under continuous heavy selling pressure because someone is constantly buying to support the current price level. Then I ask myself - who are the buyers? It has to be smart money. BXRX is not a business that sits there doing nothing for fun; it has a drug approved by FDA earlier this year and it's making progress quickly to ramp up sales. This is not just my speculation: this hypothesis has been reaffirmed by the institutional investors (the smart money) by paying a premium to get over 20M shares and warrants. Although it may not be the same institutions who bought shares on the open market, it clearly shows that the smart money wants the shares.


The share count have been increasing rapidly so far this year. I compiled the following table to look at the change of market cap throughout the year. COVID has negatively affected the commercial activities, but the valuable asset the company holds (the drug Anjeso) remains the same since its approval. Between the first public offering in March to December 2020, many progresses have been made to prepare for commercialization, including filing patent on Orange Book, getting permanent J code for medical billing, and on-boarding the first batch of 50+ accounts. Assuming the market opportunity for Anjeso hasn't changed, I find it hard to justify why the valuation becomes 30% less now when the company is getting more ready for commercialization. If analysts and investors think the stock is undervalued back earlier this year (PT average $9.0), the current valuation is a steal to me.

Date2/21/20203/23/202012/29/2020
EventFDA approvalFirst public offeringToday
Price$9.16$3.25$1.02
# of Shares9.3M20.9M42.6M
# of Shares (Fully Diluted)12.8M36.3M78.3M
Market Cap$85M$68M$43M
Market Cap (Fully Diluted)$117M$118M$80M

In addition to the strong base setup, on 10/20/2020 when the company announced its plan to convert outstanding warrants, the stock price plunged 40% from $2.6 to $1.5, leaving a price gap on the chart. Keep in mind that 90% of the gaps end up getting filled. I recently learnt the rationale behind this and found it quite fascinating. Market makers are the participants that buy and sell the same security to narrow the spread between bid-ask spread and provide liquidity to the market. They make profits by selling the security at a higher price than what they buy. When a bad news hits, market makers see lots of market sell order before the opening of the market. Their best interest is to set the price as low as possible so when the market opens they can absorb most of shares from the sellers who sell on market orders. This sudden price drop forms the gap on the chart. However, remember market makers are there to make money by providing liquidity. The question becomes how are they going to make money after they've amassed so many cheap shares? Again, it is now their best interest to sell those shares in their inventory at a higher price - they push the price up to back where they were, and the gap will get filled. Yes, I'm aware that not all gaps are created equal and 10% of those never got filled, but 90% odd is still in my favor. It's just a game of statistics.


Non-opioid drug competitive landscape
I'm not a medical expert in any sense, but I'm still trying to put together a competitive landscape in the table below so that I can understand the potential market opportunity for Anjeso. 
DrugAnjesoExparelZynrelefOfirmevCaldolorDylojectToradol
CompanyBaudax Bio Inc (BXRX)Pacira Biosciences Inc (PCRX)Heron Therapeutics Inc (HRTX)Cadence Pharmaceuticals (CADX)Cumberland Pharmaceuticals, Inc. (CPIX)Hospira, Inc. (HSP)Generic
Duration24 hours72 hours72 hours6 hours6 hours6 hours6 hours
Drug Price$94.00 / dose$334.18 / doseFDA approval pending
$47.37 / dose
$173.84 / 4 doses
$78.60 / 4 doses
$9.84 / day
Market Valuation$80M (fully diluted)$2.56B$2BAcquired by Mallinckrodt plc for $1.4B$46.01M

Peak sales$250M (Est.)$470M
$545M (Est.)
Current revenue $84.90M comes from other drugs
$340M
$5.2M
($42M sales comes from other products)
No meaningful sales

The two failed drugs Caldolor and Dyloject have very similar profile with the generic drug, Toradol, with effective duration for only 6 hours. In contrast, Anjeso has a special position among all, being the only drug that provides 24 hour pain relief duration and competitive pricing compared to other brands. Many bears are concerned that the cheap generic Toradol will limit the growth of Anjeso. However, according to BXRX, their ambition is really to gain more market share from the traditional opioid treatment and to target at those physicians who are open-minded to experiment with different kinds of new non-opioid solutions. With the public sentiment shifting away from opioid use (e.g. U.S. Sues Walmart, Alleging Role in Fueling Opioid Crisis), I believe there is still a significant opportunity for non-opioid drugs to take over. If I discount analysts' estimate for peak sales and assume BXRX can only achieve 20% of the target, given average P/S ratio 4 across the industry, Anjeso should have a fair market cap of $200M which is more than double of what it has right now even based on a fully diluted basis. If BXRX can really hit that estimate, the upside is 10X. The risk and reward looks very attractive to me.

Here is the comment from John Harlow, chief commercial officer at BXRX about their competitive landscape:
"A certain number of accounts are not spending any branded dollars, including for Ofirmev and Exparel, for non-opioids. They prefer opioids and ketorolac and we’re not going to win the clinical discussion. However, a significant opportunity exists in about 2,000 accounts beyond what Ofirmev has sewn up"
"From a physician standpoint, we have done the same type of segmentation work among orthopedic, colorectal and general surgeons. We have those who want to reduce opioids, we have physicians who love ketorolac and think it’s an oldie but goodie and don’t want to change, and we have a handful we somewhat label as ‘spreaders’ because they like to use all products."


Cash runway and cost reduction
I have to admit, the public offering in March 2020 was absolutely mismanaged. The management failed to contemplate a situation where they need to raise more capital so soon and the stock price is lower than the warrants' exercise price. In order to attract additional capital, they were forced to exchange the existing warrants with newly-issued shares for free in October. That's the main reason for the significant increase in the share count.

With that said, the company was still able to raise capitals via two private placements that have successfully added $20M to its balance sheet in December. Based on the most recent 10Q before the capital raise, BXRX has $24M cash on its balance sheet and burnt $11M cash in the same quarter. In the quarterly press release, the company has announced to reduce the workforce to save an annualized cost of $10.6M and there will be significant cost reductions made for 2021 manufacturing and launch related activities (unspecified amount). Let's spread the $10.6M across 4 quarters equally and assume $1-2M cost saving per quarter from manufacturing. It gives us $6-7M cash burn per quarter moving forward. Adding the $20M capital that was recently raised, that $44M cash position should be giving BXRX at least 4 more quarters to run until the end of 2021 before it needs any additional financing. In addition, after the recent two private placements, although another 20M warrants are now overhanging, if exercised, that will raise another $20M, or 2 more quarters, for the company to operate.

How much longer will the pandemic last? Nobody knows, but with all the recent vaccine news, I believe it will take less than 1 year for the economy to gradually recover and for hospital to resume more elective surgeries. The company has taken all the necessary measures that will help them operate more sustainably while the pandemic is still going on.


Conclusion
BXRX has been a bloodbath this year for many investors who got in too early. Many investors have experienced 50-80% drop in value and many are even concerned the company is not able to generate any revenue after they cut the sales force. This is exactly my favorite time to buy shares when the sentiment is at its lowest. When the market feels so hopeless and hateful about a stock, any positive news can reverse its trend easily. Due to the favorable setup and risk reward profile, BXRX has become one of my largest positions in my portfolio. The stock price may consolidate around this lowest level for a little bit longer, but once the tax-loss harvesting season is over, I believe the company is well positioned for a strong rebound and beyond.